Combining Checkpoint and Tyrosine Kinase Inhibitor in the Treatment of Renal Cell Carcinoma

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：247 / 247
页数：1
相关论文
共 50 条
  • [41] The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases
    Aytekin, Aydin
    Ciltas, Aydin
    Sahinli, Hayriye
    Benekli, Mustafa
    JOURNAL OF BUON, 2016, 21 (01): : 281 - 282
  • [42] Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
    Vasudev, Naveen S.
    Larkin, James M. G.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 333 - 342
  • [43] Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma
    Chon, Hye Yeon
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 83 (02): : 78 - 80
  • [44] Application of extended immunotherapy in advanced clear cell renal cell carcinoma treated with fi rst-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor
    Wang, Q.
    Zhang, X.
    Zhu, Q.
    Zeng, H.
    Chen, J.
    Zhao, J.
    Dai, J.
    Sun, G.
    Liu, Z.
    Shen, P.
    ANNALS OF ONCOLOGY, 2024, 35
  • [45] Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
    Xie, Diyang
    Sun, Qiman
    Wang, Xiaoying
    Zhou, Jian
    Fan, Jia
    Ren, Zhenggang
    Gao, Qiang
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [46] Focused Ultrasound-Triggered Release of Tyrosine Kinase Inhibitor From Thermosensitive Liposomes for Treatment of Renal Cell Carcinoma
    Abshire, Caleb
    Murad, Hakm Y.
    Arora, Jaspreet S.
    Liu, James
    Mandava, Sree Harsha
    John, Vijay T.
    Khismatullin, Damir B.
    Lee, Benjamin R.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (05) : 1355 - 1362
  • [47] Clinical outcomes of tyrosine kinase inhibitors immediately after immune checkpoint inhibitors in renal cell carcinoma
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyousuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Uemura, Motohide
    Nonomura, Norio
    ANNALS OF ONCOLOGY, 2022, 33 : S497 - S497
  • [48] Tyrosine-kinase inhibitor sorafenib (S) in treatment of metastatic renal cell carcinoma cancer (mRCC) with lung metastases
    Popova, Irina L.
    Vladimirova, Liubov Yu
    Abramova, Natalya A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Treatment of advanced renal cell carcinoma after tyrosine kinase inhibitor therapy: first experiences with Everolimus (Afinitor®) in practice
    Johannsen, M.
    Kempkensteffen, C.
    Miller, K.
    Weikert, S.
    ONKOLOGIE, 2010, 33 : 90 - 90
  • [50] Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis
    Yoshida, Kazuhiko
    Nagasaka, Naoki
    Kondo, Tsunenori
    Kobari, Yuki
    Ishihara, Hiroki
    Fukuda, Hironori
    Iizuka, Junpei
    Ishida, Hideki
    Takagi, Toshio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1538 - 1547
12345